1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study

Background

Patient associations are vital for supporting patients (pts) with rare tumors like sarcomas, yet awareness varies among individuals. This study aims to identify factors contributing to awareness inequality, that could be addressed to improve sarcoma management.

Methods

We performed a multicentric cross-sectional study of 365 sarcoma pts treated in 2021 at 9 Spanish hospitals, including 4 official sarcoma-expert centers (SECs). Data were collected through an anonymous survey capturing demographic, socioeconomic and clinical information, as well as patient association awareness and opinions. To evaluate factors associated with patient awareness, odds ratios (ORs) were calculated using multivariable logistic models.

Results

Patient characteristics are detailed in the table. Higher income is associated with enhanced cancer association awareness (OR for high vs. low incomes: 2.71; 95% Confidence Interval [CI], 1.21-6.30); similarly, higher educational level is associated with higher sarcoma association awareness (OR university vs. elementary studies, 3.87; CI, 1.34-11.79) and more contact with associations (p=0.008). Awareness and contact with associations show significant regional disparities (p6-month vs. 12% in

Conclusions

Patient association awareness among sarcoma patients display significant disparities influenced by age, socioeconomic status, education, geographic region and treatment center.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

G. Villacampa: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabrer, GSK; Financial Interests, Personal, Invited Speaker, Internal discussion about the interpretation of some published results: Pfizer; Financial Interests, Personal, Other, Collaborations with specific projects: Reveal Genomics. A. Sebio Garcia: Financial Interests, Personal, Advisory Board: Boehringer Ingelhaim, PharmaMar, Deciphera; Financial Interests, Personal, Other, Travel expenses: Cebiotex, Merck; Non-Financial Interests, Member of Board of Directors: Spanish Sarcoma Group. J. Martinez Trufero: Financial Interests, Personal, Advisory Board, Advisory Board meeting: PharmaMar, Eisai; Financial Interests, Personal, Invited Speaker: Roche, Eisai, Merck, Medicamenta, MSD, Ipsen; Financial Interests, Personal, Advisory Board, Advisory Board Meeting: GSK, Deciphera, Boehringer Ingelheim, Eisai; Financial Interests, Personal, Other, Meeting travel expenses: Roche, PharmaMar; Financial Interests, Institutional, Local PI, Clinical trial: RAIN Therapeutics, Blueprint, Lilly, Kariopharm Therapeutics, Syneos Health, Boehringer, Ayala Pharmaceuticals, SynOx Therapeutics, BioNTech, Daiichi Sankyo; Non-Financial Interests, Member of Board of Directors, Spanish group of Sarcoma Research: GEIS Group; Non-Financial Interests, Member of Board of Directors, Spanish Group of Head and Neck cancer Research: TTCC Group. A. Redondo: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK, PharmaMar, Pharma&; Financial Interests, Personal, Advisory Board: MSD, Astra Zeneca, GSK, PharmaMar, Boehringer Ingelheim; Financial Interests, Institutional, Local PI: Roche, Eisai, PharmaMar. A. Molina Diaz: Financial Interests, Personal, Invited Speaker: BMS, Ipsen, PharmaMar, Merck, AstraZeneca, Pfizer, Roche; Financial Interests, Personal, Advisory Board: BMS, Pfizer; Financial Interests, Institutional, Local PI: BMS, Merck, MSD. J. Tabernero: Financial Interests, Personal, Advisory Board, scientific consultancy role: Orion Biotechnology, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc., Ikena Oncology, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Scandion Oncology, Ona Therapeutics, Sotio Biotech, Inspirna Inc, Scorpion Therapeutics, Tolremo Therapeutics, CARSgen Therapeutics, hC Bioscience Inc, Takeda Pharmaceuticals International AG, Alentis Therapeutics, Immodulon Therapeutics; Financial Interests, Personal, Invited Speaker, educational collaboration: Medscape Education, Physicians Education Resource (PER), PeerView Institute for Medical Education, Imedex/HMP; Financial Interests, Personal, Advisory Board: Cardiff Oncology, Aveo Oncology; Financial Interests, Personal, Stocks/Shares: Oniria Therapeuics, 1TRIALSP, Alentis Therapeutics, Pangaea Oncology; Financial Interests, Institutional, Research Grant, ACRCelerate: Colorectal Cancer Stratified: Fundación Científica de la Asociación Española Contra el Cáncer; Financial Interests, Institutional, Research Grant, OPTIMISTICC: Opportunity to Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer: Cancer Research UK; Financial Interests, Institutional, Funding, Clinical Trials & Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, Janssen-Cilag International NV, Merck Health KGAA, Merck, Sharp & Dohme de España, SA, Novartis Farmacéutica SA, PharmaMar SA, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA, Inc, BeiGene, Boehringer Ingelheim, Menarini, Merus N V, Pfizer, Mirati; Non-Financial Interests, Member of Board of Directors, Board of Directors: Cancer Core Europe, Spanish Association Against Cancer -AECC; Non-Financial Interests, Member of Board of Directors, General Assembly: Horizon Europe Cancer Mission; Non-Financial Interests, Leadership Role, External Scientific Committee: Institute for Health Research INCLIVA – Clinical Hospital of Valencia, IdiSNA –Universidad de Navarra; Non-Financial Interests, Leadership Role, Scientific Advisory Board: Spanish National Cancer Research Centre (CNIO); Non-Financial Interests, Advisory Role, International Scientific Evaluation Committee: Bosch Health Campus (BHC); Non-Financial Interests, Advisory Role, Review Board: National Decade Against Cancer (NCT) - German Consortium for Translational Cancer Research (DKTK); Non-Financial Interests, Advisory Role, Scientific Advisory Board: Karolinska Comprehensive Cancer Centre; Non-Financial Interests, Advisory Role, International Review Committee (IRC): Oncode Institute; Non-Financial Interests, Advisory Role, Scientific Advisory Board (SAB): Oslo University Hospital Comprehensive Cancer Centre (OUH CCC); Non-Financial Interests, Leadership Role, Governance Advisory Committee: European Organization for Research and Treatment of Cancer -EORTC; Non-Financial Interests, Leadership Role, Vice Chairman: World Innovative Networking (WIN) Consortium in Personalized Cancer Medicine; Non-Financial Interests, Other, Coordinating PI & Steering Committee Member. Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutical LP, Boehringer Ingelheim, MedImmune, Menarini, Merck Healthcare KGAA, Merck, Sharp & Dohme de España SA, Pfizer, Servier; Non-Financial Interests, Principal Investigator, Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutics LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, MedImmune, Menarini, Merck Healthcare KGAA, Merck, Sharp & Dohme de España SA, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc; Non-Financial Interests, Other, Steering Committee Member. Clinical Trials & Research: Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, Merus NV, Taiho Pharma USA Inc; Non-Financial Interests, Other, Coordinating PI. Clinical Trials & Research: Mirati; Non-Financial Interests, Member: AACR, ASCO, EACR, EORTC, SEOM; Other, President: Oncology Master Plan – Catalonia Department of Health; Other, Advisory Committee: Advisory Committee on Pharmaceutical Provision Financing under the Spanish National Health System. C.M. Valverde Morales: Financial Interests, Personal, Advisory Board: PharmaMar, Bayer, GSK, Mundipharma, Lilly, Boehringer Ingelheim, Deciphera, NEC OncoImmunity AS; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Institutional, Local PI, Clinical Trial: Adaptimmune, Karyopharm, Lilly, Foghorn Therapeutics, Ayala therapeutics, Inhibrx, Philogen, Intensity Therapeutics; Financial Interests, Institutional, Coordinating PI, Clinical Proyect: Bayer; Financial Interests, Institutional, Local PI, Clinical Trial, clinical project: Boheringer Ingelheim; Financial Interests, Institutional, Local PI, Clinical Trial: PharmaMar, PTC Therapeutics; Financial Interests, Institutional, Coordinating PI, Clinical Trial: Peptomyc S.L; Non-Financial Interests, Member of Board of Directors, President 2018-ongoing: GEIS- Spanish Sarcoma Group for Research. C. Serrano: Financial Interests, Personal, Advisory Board: Deciphera Pharmaceuticals, Blueprint Medicines, Immunicum AB, IDRX, CogentBio, Newbay; Financial Interests, Personal, Invited Speaker: PharmaMar, Roche; Financial Interests, Institutional, Research Grant: IDRX; Financial Interests, Institutional, Steering Committee Member: Deciphera, Newbay; Financial Interests, Institutional, Local PI: IDRX, CogentBio; Non-Financial Interests, Member of Board of Directors: Spanish Group for Sarcoma Research (GEIS), Spanish Society of Medical Oncology (SEOM); Non-Financial Interests, Other, Faculty member: European Society of Medical Oncology (ESMO); Other, Travel Grant: PharmaMar, Pfizer, Bayer AG, Gilead. All other authors have declared no conflicts of interest.